Filing Flows › Comparisons › AGEN vs MAZE
Agenus vs Maze Therapeutics: AGEN and MAZE compared
Agenus is the larger company: $31.5M of revenue in its latest quarter (Q3 2026) against $20.0M for Maze Therapeutics (Q1 2026). Agenus is more profitable, with an operating margin of 36.2% against -132.8%.
Where the money goes: AGEN and MAZE
Agenus (AGEN) · Q3 2026
Agenus, Q3 2026: revenue $31.5M (+4% year over year), operating margin 36.2%, net earnings $1.5M, operating cash flow −$20.1M. The chart follows the revenue to costs, profit and cash.
Maze Therapeutics (MAZE) · Q1 2026
Maze Therapeutics, Q1 2026: revenue $20.0M, operating margin -132.8%, net loss $24.2M, operating cash flow −$39.1M. The chart follows the revenue to costs, profit and cash.
| Agenus (AGEN) | Maze Therapeutics (MAZE) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 2026 |
| Revenue | $31.5M | $20.0M |
| Revenue growth, Y/Y | +4% | — |
| Operating margin | 36.2% | -132.8% |
| Net earnings | $1.5M | −$24.2M |
| Net margin | 4.8% | -121.0% |
| Operating cash flow | −$20.1M | −$39.1M |
Where the revenue comes from
Agenus
- Non Cash Royalty Revenue Related to the Sale of Future Royalties: $25.4M (81%)
- Pre Commercial Product Revenue: $6.1M (19%)
Questions
Which is bigger, Agenus or Maze Therapeutics?
Agenus is the larger company: $31.5M of revenue in its latest quarter (Q3 2026) against $20.0M for Maze Therapeutics (Q1 2026).
Is Agenus or Maze Therapeutics growing faster?
Agenus is more profitable, with an operating margin of 36.2% against -132.8%.
More: Agenus earnings · how Agenus makes money · Maze Therapeutics earnings · how Maze Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed May 12, 2026). Fiscal quarters can end on different dates. Not investment advice.